select a format

Single User License
USD 3500 INR 224630
Site License
USD 7000 INR 449260
Corporate User License
USD 10500 INR 673890

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Pipeline Review, H2 2016

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0704TDB
  • |
  • Pages: 40
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Pipeline Review, H2 2016', provides in depth analysis on Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)

The report reviews Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Overview 6

Therapeutics Development 7

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Products under Development by Stage of Development 7

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Products under Development by Therapy Area 8

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Products under Development by Indication 9

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Products under Development by Companies 13

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Companies Involved in Therapeutics Development 21

Altor BioScience Corp 21

Cytune Pharma SAS 22

Nektar Therapeutics 23

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Drug Profiles 24

ALT-803-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CYP-0150-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibody Conjugates for Infectious Disease and Oncology-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

NKTR-255-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Recombinant Protein for Metabolic Disorders-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Dormant Projects 31

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)-Featured News & Press Releases 32

Oct 28, 2016: Nektar Therapeutics to present data on NKTR-255 at the 2016 Society for Immunotherapy of Cancer Annual Meeting 32

Apr 27, 2016: Beike Biotechnology Unveils Comprehensive Cancer-treating Immunotherapy Program 32

Oct 06, 2015: Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin Lymphoma 32

Nov 04, 2014: Altor BioScience Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma Supported by a Newly Awarded Phase II SBIR Grant from NCI 33

Aug 19, 2014: Altor BioScience Awarded SBIR Phase II Grant by NCI for Clinical Development of its Novel IL-15 Super Agonist for Non-muscle Invasive Bladder Cancer 34

Aug 15, 2013: Altor BioScience Launches its Proprietary IL-15 Superagonist ALT-803 into Clinical Trials against Cancer 35

Sep 27, 2012: Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers 36

Apr 30, 2012: Altor And Melanoma Research Alliance To Co-Support Clinical Studies Of ALT-803 To Treat Metastatic Melanoma 37

Aug 17, 2011: Altor Receives $225,279 SBIR Phase I Grant For Research On ALT-803 To Treat Bladder Cancer 37

Jun 28, 2011: Florida Biologix Signs Manufacturing Agreement With Altor BioScience 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Altor BioScience Corp, H2 2016 21

Pipeline by Cytune Pharma SAS, H2 2016 22

Pipeline by Nektar Therapeutics, H2 2016 23

Dormant Projects, H2 2016 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corp, Cytune Pharma SAS, Nektar Therapeutics

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Therapeutic Products under Development, Key Players in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Therapeutics, Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Pipeline Overview, Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Pipeline, Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com